11-2570663-C-G
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000218.3(KCNQ1):āc.513C>Gā(p.Tyr171Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000186 in 1,612,506 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ). Synonymous variant affecting the same amino acid position (i.e. Y171Y) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000218.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
KCNQ1 | NM_000218.3 | c.513C>G | p.Tyr171Ter | stop_gained | 3/16 | ENST00000155840.12 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
KCNQ1 | ENST00000155840.12 | c.513C>G | p.Tyr171Ter | stop_gained | 3/16 | 1 | NM_000218.3 | P1 | |
KCNQ1 | ENST00000335475.6 | c.132C>G | p.Tyr44Ter | stop_gained | 3/16 | 1 | |||
KCNQ1 | ENST00000496887.7 | c.252C>G | p.Tyr84Ter | stop_gained | 4/16 | 5 | |||
KCNQ1 | ENST00000646564.2 | c.478-12772C>G | intron_variant |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152180Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.00000802 AC: 2AN: 249480Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135350
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1460326Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 726568
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152180Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74350
ClinVar
Submissions by phenotype
Beckwith-Wiedemann syndrome;C1837014:Atrial fibrillation, familial, 3;C1865019:Short QT syndrome type 2;C4551509:Jervell and Lange-Nielsen syndrome 1;C4551647:Long QT syndrome 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Sep 02, 2021 | - - |
Long QT syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 22, 2023 | This sequence change creates a premature translational stop signal (p.Tyr171*) in the KCNQ1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in KCNQ1 are known to be pathogenic (PMID: 9323054, 19862833). This variant is present in population databases (rs139042529, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with autosomal dominant long QT syndrome and autosomal recessive Jervell and Lange-Nielsen syndrome (PMID: 11216980, 12051962, 17470695, 26187847). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 53056). For these reasons, this variant has been classified as Pathogenic. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 17, 2023 | The p.Y171* pathogenic mutation (also known as c.513C>G), located in coding exon 3 of the KCNQ1 gene, results from a C to G substitution at nucleotide position 513. This changes the amino acid from a tyrosine to a stop codon within coding exon 3. This mutation has been detected in individuals with Jervell and Lange-Nielsen syndrome who had an additional mutations in KCNQ1 (Piippo K et al. J Am Coll Cardiol, 2001 Feb;37:562-8; Wang Z et al. Mol Genet Metab, 2002 Apr;75:308-16). This variant has also been detected in individuals from a long QT syndrome registry (Moss AJ et al. Circulation, 2007 May;115:2481-9). An in vitro functional study reported this variant to result in no potassium channel current (Dotzler SM et al. Circulation, 2021 Apr;143:1411-1425). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at